ORIC Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ORIC Pharmaceuticals generated cash of -$85,688,000, which is less than the previous year. Cash used in financing activities reached the amount of $85,658,000 last year. Net change in cash is therefore -$43,433,000.
Cash Flow
| 2017 | -20.83M | -292K | 260K |
|---|---|---|---|
| 2018 | -20.68M | -508K | 38.00M |
| 2019 | -23.53M | -768K | 70.82M |
| 2020 | -45.26M | -215.95M | 250.51M |
| 2021 | -59.54M | 158.43M | 49.13M |
| 2022 | -75.14M | -109.24M | 25.62M |
| 2023 | -85.68M | -43.40M | 85.65M |
ORIC Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 67.30M | 226.47M | 78.44M | 89.15M | 42.63M | 25.81M | 46.68M |
Operating activities | |||||||
Net income | -100.69M | -89.12M | -78.71M | -73.70M | -26.88M | -21.36M | -22.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.03M | 966K | 897K | 970K | 1.02M | 903K | 900K |
Stock-based compensation expense | 15.22M | 14.46M | 12.85M | 5.27M | 1.09M | 0 | 217 |
| Deferred income tax benefit | 15.22M | 14.46M | 12.85M | 5.27M | 1.09M | 0 | 217 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.27M | -1.47M | 2.93M | 4.30M | 986K | -410K | 6K |
Cash generated by operating activities | -85.68M | -75.14M | -59.54M | -45.26M | -23.53M | -20.68M | -20.83M |
Investing activities | |||||||
Purchases Of Investments | -239.24M | -238.12M | -69.62M | -225.48M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -849K | -2.07M | -939K | -667K | -768K | -525K | -486K |
Acquisitions Net | 0 | 2.07M | 1.37M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -43.40M | -109.24M | 158.43M | -215.95M | -768K | -508K | -292K |
Financing activities | |||||||
Common Stock Issued | 85M | 25M | 50M | 271.30M | 70.92M | 0 | 260K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 85.65M | 25.62M | 49.13M | 250.51M | 70.82M | 38.00M | 260K |
Net Change In Cash | -43.43M | -159.16M | 148.02M | -10.71M | 46.52M | 16.81M | -20.86M |
Cash at end of period | 23.87M | 67.30M | 226.47M | 78.44M | 89.15M | 42.63M | 25.81M |
| Data source | Data source | Data source | Data source |